The release of the hormone is reliant on various components of the endocrine system working together. Scientists researching this phenomenon have explored the use of artificially created peptides which can mimic its natural mode of signalling. CJC-1295 is one such drug and is most closely associated with its effect on growth hormone-releasing hormone, or GHRH. Its mechanism has attracted significant attention but exploration into use and long term consequences are still at an early stage.
How Does the Peptide Work?
GHRH is produced in the hypothalamus and is involved in stimulating the secretion of growth hormone from the pituitary gland. This is a normal hormonal message.
In CJC-1295, mimics some of the actions of GHRH. When interacting with GHRH receptor sites, it could alter the signalling of the release of growth hormone. Some of the CJC-1295 derivatives also include a Drug Affinity Complex or DAC which alters the duration of activity.
This prolonged activity has been investigated by researchers because it presents an alternative approach to analysing the growth hormone pathway in comparison to naturally occurring GHRH.
What Has Research Looked At?
Most of the scientific community’s interest in CJC-1295 has been related to its effects on growth hormone, and on IGF-1 (Insulin-like Growth factor 1). These hormones are coupled together and involved in many different processes of tissue growth and metabolism.
This association has also led to speculation on the potential influence on body composition and physical recovery. However such conjectures should be separated from the confirmed medical benefits. Alteration in hormone concentrations is not synonymous with health or physical advantage. There is also limited robust human data, with regard to long-term use.
Safety and Remaining Questions
Hormonal intervention interventions that alter hormone signalling should be subjected to thorough research. As growth hormone and IGF-1 act on several tissues, potential effects related to metabolism, glucose homeostasis and fluid balance have to be taken into account by investigators.
A further point is the quality of products available outside of established research or medical environments. Peptides purchased without regulation may not reliably include the dose stated on the packaging and the sterility of the drugs may also be questionable. Accordingly, these factors are factors why controlled research is especially important in the assessment of both benefits and risks.
Conclusion
Provides researchers with a method of investigating the effects of GHRH related signalling on growth hormone secretion. Although its biological action is known, there are still questions relating to its clinical uses and safety over an extended period. Further human research will be necessary to establish whether the peptide has any real clinical potential.